Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison
Aims To estimate the relative treatment effect between the fixed‐ratio combinations iGlarLixi and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled on a glucagon‐like peptide 1 receptor agonist. Materials and Methods A syste...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2020-11, Vol.22 (11), p.2170-2178 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2178 |
|---|---|
| container_issue | 11 |
| container_start_page | 2170 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 22 |
| creator | Home, Philip D. Aroda, Vanita R. Blonde, Lawrence Guyot, Patricia Shaunik, Alka Fazeli, Mir Sohail Goswami, Hardik Kalra, Sanjay Pourrahmat, Mir‐Masoud |
| description | Aims
To estimate the relative treatment effect between the fixed‐ratio combinations iGlarLixi and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled on a glucagon‐like peptide 1 receptor agonist.
Materials and Methods
A systematic literature review of randomized controlled trials followed by an indirect treatment comparison was performed to compare the efficacy and safety of the available fixed‐ratio combinations. Main outcomes were glycated haemoglobin (HbA1c) change and target achievement [ |
| doi_str_mv | 10.1111/dom.14136 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2420632778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2420632778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3036-7236395efc9120e5da9cb3f0c29b1f37075062a3cfad99964fe41cd6eec488fe3</originalsourceid><addsrcrecordid>eNp1kc1uFDEMx0cIREvhwAsgS1zgsG0-ZueDW9WWUmlRL3AeeRNnSclMpkmmy9x4BJ6PI09Culs4IOGLbfnnvy39i-IlZ8c8x4n2_TEvuaweFYe8rOSCS1E93tVi0bRMHBTPYrxhjJWyqZ8WB3ksatHWh8XPC2OsQjUDDhoiGkozeAP20mFY2W8W7ijEKcLVOW1WNiDYAVBPLkXY2vQF0jwSCNAW15Qo5jFqup0wkZtB-SEF7xxpWM-wcZPCjR9-ff_h7FeCkcZkNeWWQyCVOx_gHrAxxXeAEOeYqMdkFTibKGCaAmX0ztJ2968dtM2bCVIgTD0NKZ_sRww2-uF58cSgi_TiIR8Vn99ffDr7sFhdX16dna4WSjJZLWohK9kuyaiWC0ZLja1aS8OUaNfcyJrVS1YJlMqgbtu2Kg2VXOmKSJVNY0geFW_2umPwtxPF1PU2KnIOB_JT7EQpWCVFXTcZff0PeuOnMOTvMlXzpWibSmTq7Z5SwccYyHRjsD2GueOsuze8y4Z3O8Mz--pBcVr3pP-SfxzOwMke2FpH8_-VuvPrj3vJ31vjvBw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471529862</pqid></control><display><type>article</type><title>Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Home, Philip D. ; Aroda, Vanita R. ; Blonde, Lawrence ; Guyot, Patricia ; Shaunik, Alka ; Fazeli, Mir Sohail ; Goswami, Hardik ; Kalra, Sanjay ; Pourrahmat, Mir‐Masoud</creator><creatorcontrib>Home, Philip D. ; Aroda, Vanita R. ; Blonde, Lawrence ; Guyot, Patricia ; Shaunik, Alka ; Fazeli, Mir Sohail ; Goswami, Hardik ; Kalra, Sanjay ; Pourrahmat, Mir‐Masoud</creatorcontrib><description>Aims
To estimate the relative treatment effect between the fixed‐ratio combinations iGlarLixi and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled on a glucagon‐like peptide 1 receptor agonist.
Materials and Methods
A systematic literature review of randomized controlled trials followed by an indirect treatment comparison was performed to compare the efficacy and safety of the available fixed‐ratio combinations. Main outcomes were glycated haemoglobin (HbA1c) change and target achievement [<6.5% and <7.0% (<48 and <53 mmol/mol)], fasting plasma glucose, self‐monitored plasma glucose, body weight, and incidence and rate of hypoglycaemia.
Results
From 4850 s screened, 78 qualified for full‐text article review and two randomized controlled trials were included. Baseline characteristics were similar in the two studies. The mean difference at 26 weeks between IDegLira and iGlarLixi was −0.36 (95% credible intervals −0.58, −0.14) % [−3.9 (−6.3, −1.5) mmol/mol] for HbA1c and −1.0 (−1.6, −0.4) mmol/L for fasting plasma glucose. No significant differences were found in HbA1c target attainment, preprandial or postprandial self‐monitored plasma glucose, or body weight change. Formal comparisons of hypoglycaemia were limited by differences in definitions between the studies: in non‐sulphonylurea users, incidence was 28% for IDegLira (‘confirmed’ at ≤3.1 mmol/L); for iGlarLixi, incidence was 9% (‘documented symptomatic’ at <3.0 mmol/L).
Conclusions
Results of this indirect treatment comparison using two studies suggest iGlarLixi and IDegLira appear to offer similar benefits for HbA1c target achievement. However, the findings suggest differences in other glycaemia results and hypoglycaemia, which may reflect differences in study design and titration approaches.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.14136</identifier><identifier>PMID: 32627297</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Agonists ; Blood glucose ; Body weight ; Clinical trials ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Fasting ; fixed‐ratio combination ; GLP-1 receptor agonists ; Glucagon ; glucagon‐like peptide‐1 receptor agonist ; Glucose ; Hemoglobin ; hypoglycaemia ; Hypoglycemia ; indirect treatment comparison ; Insulin ; Literature reviews ; Peptides ; Plasma ; Systematic review ; Titration</subject><ispartof>Diabetes, obesity & metabolism, 2020-11, Vol.22 (11), p.2170-2178</ispartof><rights>2020 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3036-7236395efc9120e5da9cb3f0c29b1f37075062a3cfad99964fe41cd6eec488fe3</citedby><cites>FETCH-LOGICAL-c3036-7236395efc9120e5da9cb3f0c29b1f37075062a3cfad99964fe41cd6eec488fe3</cites><orcidid>0000-0001-5187-710X ; 0000-0003-0492-6698 ; 0000-0002-7706-4585</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.14136$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.14136$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32627297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Home, Philip D.</creatorcontrib><creatorcontrib>Aroda, Vanita R.</creatorcontrib><creatorcontrib>Blonde, Lawrence</creatorcontrib><creatorcontrib>Guyot, Patricia</creatorcontrib><creatorcontrib>Shaunik, Alka</creatorcontrib><creatorcontrib>Fazeli, Mir Sohail</creatorcontrib><creatorcontrib>Goswami, Hardik</creatorcontrib><creatorcontrib>Kalra, Sanjay</creatorcontrib><creatorcontrib>Pourrahmat, Mir‐Masoud</creatorcontrib><title>Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aims
To estimate the relative treatment effect between the fixed‐ratio combinations iGlarLixi and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled on a glucagon‐like peptide 1 receptor agonist.
Materials and Methods
A systematic literature review of randomized controlled trials followed by an indirect treatment comparison was performed to compare the efficacy and safety of the available fixed‐ratio combinations. Main outcomes were glycated haemoglobin (HbA1c) change and target achievement [<6.5% and <7.0% (<48 and <53 mmol/mol)], fasting plasma glucose, self‐monitored plasma glucose, body weight, and incidence and rate of hypoglycaemia.
Results
From 4850 s screened, 78 qualified for full‐text article review and two randomized controlled trials were included. Baseline characteristics were similar in the two studies. The mean difference at 26 weeks between IDegLira and iGlarLixi was −0.36 (95% credible intervals −0.58, −0.14) % [−3.9 (−6.3, −1.5) mmol/mol] for HbA1c and −1.0 (−1.6, −0.4) mmol/L for fasting plasma glucose. No significant differences were found in HbA1c target attainment, preprandial or postprandial self‐monitored plasma glucose, or body weight change. Formal comparisons of hypoglycaemia were limited by differences in definitions between the studies: in non‐sulphonylurea users, incidence was 28% for IDegLira (‘confirmed’ at ≤3.1 mmol/L); for iGlarLixi, incidence was 9% (‘documented symptomatic’ at <3.0 mmol/L).
Conclusions
Results of this indirect treatment comparison using two studies suggest iGlarLixi and IDegLira appear to offer similar benefits for HbA1c target achievement. However, the findings suggest differences in other glycaemia results and hypoglycaemia, which may reflect differences in study design and titration approaches.</description><subject>Agonists</subject><subject>Blood glucose</subject><subject>Body weight</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Fasting</subject><subject>fixed‐ratio combination</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>glucagon‐like peptide‐1 receptor agonist</subject><subject>Glucose</subject><subject>Hemoglobin</subject><subject>hypoglycaemia</subject><subject>Hypoglycemia</subject><subject>indirect treatment comparison</subject><subject>Insulin</subject><subject>Literature reviews</subject><subject>Peptides</subject><subject>Plasma</subject><subject>Systematic review</subject><subject>Titration</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc1uFDEMx0cIREvhwAsgS1zgsG0-ZueDW9WWUmlRL3AeeRNnSclMpkmmy9x4BJ6PI09Culs4IOGLbfnnvy39i-IlZ8c8x4n2_TEvuaweFYe8rOSCS1E93tVi0bRMHBTPYrxhjJWyqZ8WB3ksatHWh8XPC2OsQjUDDhoiGkozeAP20mFY2W8W7ijEKcLVOW1WNiDYAVBPLkXY2vQF0jwSCNAW15Qo5jFqup0wkZtB-SEF7xxpWM-wcZPCjR9-ff_h7FeCkcZkNeWWQyCVOx_gHrAxxXeAEOeYqMdkFTibKGCaAmX0ztJ2968dtM2bCVIgTD0NKZ_sRww2-uF58cSgi_TiIR8Vn99ffDr7sFhdX16dna4WSjJZLWohK9kuyaiWC0ZLja1aS8OUaNfcyJrVS1YJlMqgbtu2Kg2VXOmKSJVNY0geFW_2umPwtxPF1PU2KnIOB_JT7EQpWCVFXTcZff0PeuOnMOTvMlXzpWibSmTq7Z5SwccYyHRjsD2GueOsuze8y4Z3O8Mz--pBcVr3pP-SfxzOwMke2FpH8_-VuvPrj3vJ31vjvBw</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Home, Philip D.</creator><creator>Aroda, Vanita R.</creator><creator>Blonde, Lawrence</creator><creator>Guyot, Patricia</creator><creator>Shaunik, Alka</creator><creator>Fazeli, Mir Sohail</creator><creator>Goswami, Hardik</creator><creator>Kalra, Sanjay</creator><creator>Pourrahmat, Mir‐Masoud</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5187-710X</orcidid><orcidid>https://orcid.org/0000-0003-0492-6698</orcidid><orcidid>https://orcid.org/0000-0002-7706-4585</orcidid></search><sort><creationdate>202011</creationdate><title>Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison</title><author>Home, Philip D. ; Aroda, Vanita R. ; Blonde, Lawrence ; Guyot, Patricia ; Shaunik, Alka ; Fazeli, Mir Sohail ; Goswami, Hardik ; Kalra, Sanjay ; Pourrahmat, Mir‐Masoud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3036-7236395efc9120e5da9cb3f0c29b1f37075062a3cfad99964fe41cd6eec488fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agonists</topic><topic>Blood glucose</topic><topic>Body weight</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Fasting</topic><topic>fixed‐ratio combination</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>glucagon‐like peptide‐1 receptor agonist</topic><topic>Glucose</topic><topic>Hemoglobin</topic><topic>hypoglycaemia</topic><topic>Hypoglycemia</topic><topic>indirect treatment comparison</topic><topic>Insulin</topic><topic>Literature reviews</topic><topic>Peptides</topic><topic>Plasma</topic><topic>Systematic review</topic><topic>Titration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Home, Philip D.</creatorcontrib><creatorcontrib>Aroda, Vanita R.</creatorcontrib><creatorcontrib>Blonde, Lawrence</creatorcontrib><creatorcontrib>Guyot, Patricia</creatorcontrib><creatorcontrib>Shaunik, Alka</creatorcontrib><creatorcontrib>Fazeli, Mir Sohail</creatorcontrib><creatorcontrib>Goswami, Hardik</creatorcontrib><creatorcontrib>Kalra, Sanjay</creatorcontrib><creatorcontrib>Pourrahmat, Mir‐Masoud</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Home, Philip D.</au><au>Aroda, Vanita R.</au><au>Blonde, Lawrence</au><au>Guyot, Patricia</au><au>Shaunik, Alka</au><au>Fazeli, Mir Sohail</au><au>Goswami, Hardik</au><au>Kalra, Sanjay</au><au>Pourrahmat, Mir‐Masoud</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2020-11</date><risdate>2020</risdate><volume>22</volume><issue>11</issue><spage>2170</spage><epage>2178</epage><pages>2170-2178</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>Aims
To estimate the relative treatment effect between the fixed‐ratio combinations iGlarLixi and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled on a glucagon‐like peptide 1 receptor agonist.
Materials and Methods
A systematic literature review of randomized controlled trials followed by an indirect treatment comparison was performed to compare the efficacy and safety of the available fixed‐ratio combinations. Main outcomes were glycated haemoglobin (HbA1c) change and target achievement [<6.5% and <7.0% (<48 and <53 mmol/mol)], fasting plasma glucose, self‐monitored plasma glucose, body weight, and incidence and rate of hypoglycaemia.
Results
From 4850 s screened, 78 qualified for full‐text article review and two randomized controlled trials were included. Baseline characteristics were similar in the two studies. The mean difference at 26 weeks between IDegLira and iGlarLixi was −0.36 (95% credible intervals −0.58, −0.14) % [−3.9 (−6.3, −1.5) mmol/mol] for HbA1c and −1.0 (−1.6, −0.4) mmol/L for fasting plasma glucose. No significant differences were found in HbA1c target attainment, preprandial or postprandial self‐monitored plasma glucose, or body weight change. Formal comparisons of hypoglycaemia were limited by differences in definitions between the studies: in non‐sulphonylurea users, incidence was 28% for IDegLira (‘confirmed’ at ≤3.1 mmol/L); for iGlarLixi, incidence was 9% (‘documented symptomatic’ at <3.0 mmol/L).
Conclusions
Results of this indirect treatment comparison using two studies suggest iGlarLixi and IDegLira appear to offer similar benefits for HbA1c target achievement. However, the findings suggest differences in other glycaemia results and hypoglycaemia, which may reflect differences in study design and titration approaches.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>32627297</pmid><doi>10.1111/dom.14136</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-5187-710X</orcidid><orcidid>https://orcid.org/0000-0003-0492-6698</orcidid><orcidid>https://orcid.org/0000-0002-7706-4585</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2020-11, Vol.22 (11), p.2170-2178 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2420632778 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Agonists Blood glucose Body weight Clinical trials Diabetes Diabetes mellitus (non-insulin dependent) Fasting fixed‐ratio combination GLP-1 receptor agonists Glucagon glucagon‐like peptide‐1 receptor agonist Glucose Hemoglobin hypoglycaemia Hypoglycemia indirect treatment comparison Insulin Literature reviews Peptides Plasma Systematic review Titration |
| title | Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A46%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20iGlarLixi%20versus%20IDegLira%20in%20adults%20with%20type%202%20diabetes%20inadequately%20controlled%20by%20glucagon%E2%80%90like%20peptide%E2%80%901%20receptor%20agonists:%20a%20systematic%20literature%20review%20and%20indirect%20treatment%20comparison&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Home,%20Philip%20D.&rft.date=2020-11&rft.volume=22&rft.issue=11&rft.spage=2170&rft.epage=2178&rft.pages=2170-2178&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.14136&rft_dat=%3Cproquest_cross%3E2420632778%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471529862&rft_id=info:pmid/32627297&rfr_iscdi=true |